drugset / Trial / NCT00220480

A Naturalistic Study of the Efficacy and Safety of Escitalopram in Treatment Resistant Depression

NCT00220480

Unknown 60 enrolled Sheba Medical Center
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The primary objective of this multicenter study is to evaluate the efficacy of escitalopram in treatment resistant depression (TRD), assessed by 2 consecutive failed antidepressant treatments from different classes. The last treatment received is a 6 week prospective trial with venlafaxine.

Timeline

Start
2005-02
Primary completion
2011-06
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Escitalopram Small molecule 10 mg
Subject Escitalopram Small molecule 30 mg